← Leaderboards
William Messer
Oregon Health & Science University
$6,360,195
Attributed
$6,360,195
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,360,195 · 4
By mechanism
R01$5,478,363 · 2
R21$881,832 · 2
Top collaborators
No co-investigators on record.
Most similar at Oregon Health & Science University
Same institution · by research overlap
- Seth E O'Neal$8,008,882
- Jonah B. Sacha$34,199,132
Others in their field
Other Emerging Leaders on “Immunity”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$181,310,675
- Kevin Urdahl · Seattle Children'S Hospital$84,741,409
- Ted Ross · University Of Georgia$74,507,826
- Yunda Huang · Fred Hutchinson Cancer Center$73,602,469
- Tony Moody · Duke University$66,767,417
Research focus
ImmunityMissionProspectiveBurden Of IllnessFosteringUnited States National Institutes Of HealthInnovationResponseImmuneVaccinesNeutralizing AntibodyVirusInfectionFrequenciesPublic HealthAntibodiesFutureMemory B-LymphocyteFlavivirusAntibody Titer MeasurementCellsEvaluationCohortDengue
Grant awards (18)
Flavivirus immunity in endemic and non-endemic human cohorts$562,407
R01 · FY2025 · AI · contact PI
Long Term Immunity Following Yellow Fever Vaccination$534,817
R01 · FY2024 · AI · contact PI
Flavivirus immunity in endemic and non-endemic human cohorts$385,922
R01 · FY2024 · AI · contact PI
Flavivirus immunity in endemic and non-endemic human cohorts$208,341
R01 · FY2024 · AI · contact PI
Immunogenicity of the dengue vaccine CYD-TDV in a dengue virus serotype 1 immune population$195,042
R21 · FY2024 · AI · contact PI
Long Term Immunity Following Yellow Fever Vaccination$524,622
R01 · FY2023 · AI · contact PI
Flavivirus immunity in endemic and non-endemic human cohorts$385,867
R01 · FY2023 · AI · contact PI
Immunogenicity of the dengue vaccine CYD-TDV in a dengue virus serotype 1 immune population$247,418
R21 · FY2023 · AI · contact PI
Long Term Immunity Following Yellow Fever Vaccination$437,405
R01 · FY2022 · AI · contact PI
Flavivirus immunity in endemic and non-endemic human cohorts$383,984
R01 · FY2022 · AI · contact PI
Early and long term immunity following SARS-CoV-2 infection in humans$44,999
R01 · FY2022 · AI · contact PI
Long Term Immunity Following Yellow Fever Vaccination$525,681
R01 · FY2021 · AI · contact PI
Flavivirus immunity in endemic and non-endemic human cohorts$395,704
R01 · FY2021 · AI · contact PI
Early and long term immunity following SARS-CoV-2 infection in humans$191,724
R01 · FY2021 · AI · contact PI
Long Term Immunity Following Yellow Fever Vaccination$558,757
R01 · FY2020 · AI · contact PI
Early and long term immunity following SARS-CoV-2 infection in humans$338,133
R01 · FY2020 · AI · contact PI
Dengue virus immunity in endemic and non-endemic human cohorts$193,703
R21 · FY2019 · AI · contact PI
Dengue virus immunity in endemic and non-endemic human cohorts$245,669
R21 · FY2018 · AI · contact PI